<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04558359</url>
  </required_header>
  <id_info>
    <org_study_id>57411</org_study_id>
    <nct_id>NCT04558359</nct_id>
  </id_info>
  <brief_title>Renin and Renal Biomarker Response to Angiotensin II</brief_title>
  <official_title>Renin and Renal Biomarker Response to Angiotensin II Versus Controls in Septic Shock: An Open-Label Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alexander Flannery</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Kentucky</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Septic shock continues to exert a large economic burden around the world. Several&#xD;
      developments have occurred that lead to the current study. First, angiotensin II is the&#xD;
      newest FDA approved vasopressor agent indicated for use in vasodilatory shock. Several&#xD;
      subgroups from the approval trial have indicated that angiotensin II may confer a survival&#xD;
      benefit in certain conditions, including those patients requiring continuous renal&#xD;
      replacement therapy, those with altered angiotensin I: angiotensin II ratios, and most&#xD;
      recently, those with elevated renin levels (which may serve as a surrogate for dysfunctional&#xD;
      angiotensin 1: angiotensin II ratios). This open-label, sequential period pilot study will&#xD;
      evaluate angiotensin II and biomarker response (renin) in the treatment of septic shock.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 19, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Plasma Renin Levels</measure>
    <time_frame>Until shock resolution, up to 14 days (at baseline, 3 hours, 24 hours, and shock resolution, up to 14 days)</time_frame>
    <description>Plasma renin levels will be measured from blood collected at baseline, 24 hours, and at shock resolution. Additionally, a 3-hour measurement will be included in the angiotensin II arm.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Renal Biomarkers</measure>
    <time_frame>Until shock resolution, up to 14 days (at baseline, 24 hours, and shock resolution, up to 14 days)</time_frame>
    <description>Cystatin C, NGAL will be measured from blood collected at baseline, 24 hours, and at shock resolution.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to discontinuation of catecholamines</measure>
    <time_frame>Until shock resolution, up to 14 days</time_frame>
    <description>Time from enrollment to discontinuation of catecholamines</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU Length of Stay</measure>
    <time_frame>From enrollment to ICU discharge, up to 28 days following enrollment</time_frame>
    <description>Number of days in the intensive care unit (ICU).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-hospital mortality</measure>
    <time_frame>Up to 3 months following enrollment</time_frame>
    <description>Assessment of all-cause mortality within hospital admission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal replacement therapy-free days</measure>
    <time_frame>Within 28 days of enrollment</time_frame>
    <description>Days free of renal replacement therapy from enrollment up to day 28</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety outcomes</measure>
    <time_frame>Up to 72 hours following shock resolution, no longer than 17 days from enrollment</time_frame>
    <description>Incidence of venous thromboembolism, arrhythmia, extremity hypoperfusion, delirium, new ischemic event, new infection</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Septic Shock</condition>
  <condition>Acute Kidney Injury</condition>
  <arm_group>
    <arm_group_label>Standard of Care Cohort</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in this group will receive standard of care treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Angiotensin II Cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in this group will receive angiotensin II.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard of Care</intervention_name>
    <description>These patients will receive standard of care treatment. Plasma renin levels and biomarkers of renal function will be measured.</description>
    <arm_group_label>Standard of Care Cohort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Angiotensin II</intervention_name>
    <description>These patients will receive angiotensin II in addition to standard of care treatment. Plasma renin levels and biomarkers of renal function will be measured.</description>
    <arm_group_label>Angiotensin II Cohort</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Medical ICU admission&#xD;
&#xD;
          -  Septic shock&#xD;
&#xD;
          -  Norepinephrine requirement = 0.15 mcg/kg/min for = 30 minutes (if cirrhosis,&#xD;
             norepinephrine requirement = 0.1 mcg/kg/min for = 30 minutes)&#xD;
&#xD;
          -  Kidney Disease Improving Global Outcomes stage 1 or greater AKI&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prisoner&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Acute occlusive coronary syndrome requiring intervention or acute myocardial&#xD;
             infarction of any degree&#xD;
&#xD;
          -  Purely cardiogenic shock (no distributive component)&#xD;
&#xD;
          -  Mesenteric ischemia&#xD;
&#xD;
          -  Acute ischemic stroke&#xD;
&#xD;
          -  Hemorrhagic shock&#xD;
&#xD;
          -  Active treatment of hepatorenal syndrome targeting a MAP = 65 mm Hg&#xD;
&#xD;
          -  Planned withdrawal of care within next 24 hours or no escalation of care&#xD;
&#xD;
          -  Patient enrolled in an interventional study&#xD;
&#xD;
          -  High likelihood of medical futility in using this drug:&#xD;
&#xD;
          -  3 or more vasopressors required to sustain MAP&#xD;
&#xD;
          -  Sustained norepinephrine equivalents &gt; 0.5 mcg/kg/min&#xD;
&#xD;
          -  COVID-19 positive, or high suspicion of COVID-19&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexander H Flannery, Pharm.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Kentucky</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alexander H Flannery, Pharm.D.</last_name>
    <phone>859-562-2766</phone>
    <email>alex.flannery@uky.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Kentucky HealthCare Chandler Medical Center</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander H. Flannery, Pharm.D.</last_name>
      <phone>859-323-9078</phone>
      <email>alex.flannery@uky.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>September 7, 2020</study_first_submitted>
  <study_first_submitted_qc>September 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 22, 2020</study_first_posted>
  <last_update_submitted>November 29, 2020</last_update_submitted>
  <last_update_submitted_qc>November 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Kentucky</investigator_affiliation>
    <investigator_full_name>Alexander Flannery</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Renin</keyword>
  <keyword>Angiotensin II</keyword>
  <keyword>vasopressor</keyword>
  <keyword>sepsis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shock, Septic</mesh_term>
    <mesh_term>Acute Kidney Injury</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Angiotensin II</mesh_term>
    <mesh_term>Giapreza</mesh_term>
    <mesh_term>Angiotensinogen</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

